Therapeutic advances in heart failure.
Thomas Meinertz1, Helmut Drexler1, Hanjörg Just1
1Department of Cardiology, University Hospital, Freiburg im Breisgau, FRG.
Cardiovascular Drugs and Therapy
|October 11, 2016
Summary
Certain vasodilator drugs significantly improve survival rates in congestive heart failure patients. Studies show hydralazine-nitrate combinations and enalapril reduce mortality, enhancing prognosis for heart failure management.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Annual mortality in congestive heart failure (CHF) is high, ranging from 15% to 60%.
- Previous controlled trials were often underpowered to detect survival benefits of novel CHF medications.
- Emerging evidence suggests vasodilators may improve CHF prognosis.
Purpose of the Study:
- To evaluate the impact of specific vasodilator therapies on survival in congestive heart failure.
- To review findings from recent studies on hydralazine-nitrate combinations and enalapril in CHF management.
Main Methods:
- Analysis of results from two recent clinical studies investigating vasodilator efficacy in CHF.
- Review of preliminary reports from large-scale trials on phosphodiesterase-inhibiting agents.
Main Results:
- A hydralazine-nitrate combination demonstrated a 34% reduction in 2-year mortality in one study.
- Enalapril, as an adjunct therapy, reduced 1-year mortality by 31% in another study.
- Phosphodiesterase-inhibiting agents, while not improving survival in preliminary reports, enhanced well-being in Class III-IV CHF patients.
Conclusions:
- Specific vasodilator regimens, including hydralazine-nitrate and enalapril, offer significant prognostic benefits for CHF patients.
- Further research into phosphodiesterase inhibitors may be warranted for improving quality of life in severe CHF.
Keywords:
ACE inhibitorsdigitalisdiureticsphosphodiesterase inhibitorsprognosissudden cardiac deathsurvivalMore Related Videos
08:30A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
3.3K
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
12.3K
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
497
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
497
01:30Heart Failure V: Medical Management
459
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
459
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K